COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study

Gary T Ferguson1 Pulmonary Research Institute of Southeast Michigan, Livonia, MI, USACorrespondence[email protected]

Mo Ghafouri2 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

Luyan Dai2 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA

Leonard J Dunn3 Clinical Research of West Florida, Inc, Clearwater, FL, USA

Figures & data

Table A1 Permitted medications and medication restrictions

Download CSV Display Table

Table 1 Summary of study patient demographics

Download CSV Display Table

Figure 1 Study population.

Notes: Five randomized patients did not proceed with treatment: three patients decided to not participate, one patient developed a COPD exacerbation, and one patient was unable to stop prohibited medication prior to randomization.
Abbreviations: N, number; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol metered-dose inhaler; I+A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies; AE, adverse event.

Figure 2 Kaplan–Meier curves of time to discontinuation.

Abbreviations: CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol metered-dose inhaler; I + A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies; d, days.

Figure 3 Adjusted mean of PASAPQ performance domain score time profile.

Abbreviations: PASAPQ, Patient Satisfaction and Preference Questionnaire; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol metered-dose inhaler; I + A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies.

Figure 4 Kaplan-Meier curves for time to first COPD exacerbation.

Abbreviations: COPD, chronic obstructive pulmonary disease; CVT-R, ipratropium bromide/albuterol Respimat inhaler; CVT-MDI, ipratropium bromide/albuterol metered-dose inhaler; I+A, ipratropium bromide and albuterol metered dose inhalers delivered as dual monotherapies; d, day.

Table 2 Frequency of patients (N, %) with adverse events occurring with incidence in preferred term greater than or equal to 3% by treatment, primary system organ class, and preferred term

Download CSV Display Table

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study

Table A1 Permitted medications and medication restrictions

Table 1 Summary of study patient demographics

Table 2 Frequency of patients (N, %) with adverse events occurring with incidence in preferred term greater than or equal to 3% by treatment, primary system organ class, and preferred term

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study

Figures & data

Table A1 Permitted medications and medication restrictions

Table 1 Summary of study patient demographics

Table 2 Frequency of patients (N, %) with adverse events occurring with incidence in preferred term greater than or equal to 3% by treatment, primary system organ class, and preferred term

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date